Last reviewed · How we verify

Olanzapine, risperidone

AstraZeneca · Phase 3 active Small molecule

Olanzapine and risperidone are atypical antipsychotics that work by blocking dopamine and serotonin receptors in the brain.

Olanzapine and risperidone are atypical antipsychotics that work by blocking dopamine and serotonin receptors in the brain. Used for Treatment of schizophrenia, Treatment of bipolar disorder.

At a glance

Generic nameOlanzapine, risperidone
SponsorAstraZeneca
Drug classatypical antipsychotic
TargetD2 receptor, 5-HT2A receptor
ModalitySmall molecule
Therapeutic areaPsychiatry
PhasePhase 3

Mechanism of action

They are primarily used to treat schizophrenia and bipolar disorder. By blocking dopamine and serotonin receptors, they help to reduce symptoms of psychosis and mania.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: